Business Wire1d
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
FDA accepts Arrowhead's NDA for plozasiran
Arrowhead Pharmaceuticals (NASDAQ:ARWR) said the FDA has accepted its New Drug Application for its drug plozasiran for the ...
FDA Accepts Arrowhead Pharmaceuticals' Drug Application for Genetic Disease Treatment
Arrowhead Pharmaceuticals said Friday that the Food and Drug Administration accepted the company's new drug application for its treatment of familial chylomicronemia syndrome, a severe and rare ...
Healio1d
The year in lipids: Progress in Lp(a) management and a blow to the ‘HDL hypothesis’
In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention ...
Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely
Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...
BioSpace4d
Sarepta Previews Q4 Findings, Touts Elevidys Earnings Beat
Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter ...
Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision
Agios Pharma submitted a sNDA to the FDA after two Phase III trials studying PYRUKYND (mitapivat) in thalassemia met their ...
Piper Sandler Reaffirms Their Buy Rating on X4 Pharmaceuticals (XFOR)
Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on X4 Pharmaceuticals (XFOR – Research Report) today and set a price target of ...
Investor's Business Daily on MSN5d
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...
Piper Sandler Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of ...